Emulating a Randomized Controlled Trial of Long‐Acting Insulins and Cardiovascular Events Using Real‐World Data for Patients With Type 2 Diabetes
The risk of MACE among patients with T2DM newly prescribed insulin degludec compared to insulin glargine was consistent between the overall population and the DEVOTE eligible subpopulation, while the DEVOTE ineligible population had discrepant point estimates.
Authors
- W Wang
- Vanessa C. Brunetti
- Kristian B. Filion (ORCID: https://orcid.org/0000-0001-6055-0088)
- Oriana H. Y. Yu
- Pauline Reynier
- Michael Webster‐Clark
Institutions
- Jewish General Hospital (CA)
- Amgen (United Kingdom) (GB)
- McGill University (CA)
Publication Details
- Journal
- Pharmacoepidemiology and Drug Safety
- Published
- 2026-01-01
- DOI
- https://doi.org/10.1002/pds.70313
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- McGill University
- Canadian Institutes of Health Research